Management of patients with familial hypercholesterolaemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolaemia (FH) is a common genetic disorder causing high LDL-cholesterol and premature cardiovascular disease.
• FH is frequently undiagnosed and undertreated, leading to suboptimal patient outcomes.
• Current statin therapy often fails to achieve guideline-recommended LDL-C levels in FH patients.

Purpose of the Study:

• To review current and emerging treatment strategies for managing Familial hypercholesterolaemia.
• To evaluate the efficacy and safety of various LDL-cholesterol lowering therapies in FH.
• To highlight the need for outcome data on novel FH treatments.

Main Methods:

• Literature review of studies on FH treatments.
• Analysis of efficacy and safety data for statins, ezetimibe, apheresis, mipomersen, lomitapide, and PCSK9 inhibitors.
• Assessment of current treatment guidelines and emerging therapeutic options.

Main Results:

• High-intensity statins are standard but often insufficient for FH.
• Combination therapies (statin-ezetimibe, apheresis) improve LDL-C reduction.
• Mipomersen and lomitapide show efficacy but have adverse effects (e.g., increased liver fat).
• PCSK9 inhibition is well-tolerated and highly effective in reducing LDL-C in statin-treated FH patients.

Conclusions:

• PCSK9 inhibition represents a promising therapeutic option for FH due to its efficacy and tolerability.
• Further outcome trial data are essential for establishing PCSK9 inhibitors, mipomersen, and lomitapide as standard FH treatments.
• Improved detection and management strategies are crucial for addressing the burden of FH.